Massive dissemination of a SARS-CoV-2 Spike Y839 variant in Portugal
Open Access
- 31 December 2019
- journal article
- research article
- Published by Taylor & Francis Ltd in Emerging Microbes & Infections
- Vol. 9 (1), 2488-2496
- https://doi.org/10.1080/22221751.2020.1844552
Abstract
Genomic surveillance of SARS-CoV-2 was rapidly implemented in Portugal by the National Institute of Health in collaboration with a nationwide consortium of >50 hospitals/laboratories. Here, we track the geotemporal spread of a SARS-CoV-2 variant with a mutation (D839Y) in a potential host-interacting region involving the Spike fusion peptide, which is a target motif of anti-viral drugs that plays a key role in SARS-CoV-2 infectivity. The Spike Y839 variant was most likely imported from Italy in mid-late February and massively disseminated in Portugal during the early epidemic, becoming prevalent in the Northern and Central regions of Portugal where it represented 22% and 59% of the sampled genomes, respectively, by 30 April. Based on our high sequencing sampling during the early epidemics [15.5% (1275/8251) and 6.0% (1500/24987) of all confirmed cases until the end of March and April, respectively], we estimate that, between 14 March and 9 April (covering the epidemic exponential phase) the relative frequency of the Spike Y839 variant increased at a rate of 12.1% (6.1%-18.2%, CI 95%) every three days, being potentially associated with 24.8% (20.8-29.7%, CI 95%; 3177-4542 cases, CI 95%) of all COVID-19 cases in Portugal during this period. Our data supports population/epidemiological (founder) effects contributing to the Y839 variant superspread. The potential existence of selective advantage is also discussed, although experimental validation is required. Despite huge differences in genome sampling worldwide, SARS-CoV-2 Spike D839Y has been detected in 13 countries in four continents, supporting the need for close surveillance and functional assays of Spike variants.Funding Information
- Fundação para a Ciência e Tecnologia
- Agência de Investigação Clínica e Inovação Biomédica (234_596874175)
- GenomePT project (POCI-01-0145-FEDER-022184)
- COMPETE 2020 – Operational Programme for Competitiveness and Internationalisation
- Lisboa Portugal Regional Operational Programme
- Algarve Portugal Regional Operational Programme
- European Regional Development Fund
- Fundação para a Ciência e a Tecnologia
This publication has 27 references indexed in Scilit:
- A pneumonia outbreak associated with a new coronavirus of probable bat originNature, 2020
- A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spikeScience Advances, 2019
- INSaFLU: an automated open web-based bioinformatics suite “from-reads” for influenza whole-genome-sequencing-based surveillanceGenome Medicine, 2018
- Nextstrain: real-time tracking of pathogen evolutionBioinformatics, 2018
- Multiplex PCR method for MinION and Illumina sequencing of Zika and other virus genomes directly from clinical samplesNature Protocols, 2017
- Microreact: visualizing and sharing data for genomic epidemiology and phylogeographyMicrobial Genomics, 2016
- The spike protein of SARS-CoV — a target for vaccine and therapeutic developmentNature Reviews Microbiology, 2009
- Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with ReceptorScience, 2005
- Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirusNature, 2003